Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017;38:2183–91.

Article  PubMed  Google Scholar 

Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118–25.

Article  PubMed  Google Scholar 

Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol. 2012;60:971–7.

Article  PubMed  Google Scholar 

Heras M, Chesebro JH, Fuster V, et al. High Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement. J Am Coll Cardiol. 1995;25:1111–9.

Article  CAS  PubMed  Google Scholar 

Zhang H, Dong Y, Ao X, Fu B, Dong L; CLIATHVR (Chinese Low Intensity Anticoagulant Therapy After Heart Valve Replacement) multicenter clinical study team. Comparison of antithrombotic strategies in chinese patients in sinus rhythm after bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in China. Cardiovasc Drugs Ther. 2021;35:1–10.

Russo A , Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications.J Am Coll Cardiol. 2008;51:1203–11.

Izumi C, Eishi K, Ashihara K, et al. JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J. 2020;84:2037–119.

Article  PubMed  Google Scholar 

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;2(143):e35–71.

Google Scholar 

Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab395.

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

Article  CAS  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

Article  CAS  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

Article  CAS  PubMed  Google Scholar 

Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624–32.

Article  CAS  PubMed  Google Scholar 

Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135:1273–5.

Article  PubMed  Google Scholar 

Guimarães PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42:568–71.

Article  PubMed  PubMed Central  Google Scholar 

Guimaraes HP, Lopes RD, de Barros e Silva PGM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117–26.

Izumi C, Miyake M, Fujita T, et al. Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves - real-world data from the multicenter, prospective. Observational BPV-AF Registry Circ J. 2022;86:440–8.

PubMed  Google Scholar 

Suppah M, Kamal A, Saadoun R, et al. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin k antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol. 2023;206:132–50.

Article  CAS  PubMed  Google Scholar 

Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020;40:839–45.

Article  CAS  PubMed  Google Scholar 

Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. 2023;165:58–67.

Article  PubMed  Google Scholar 

Beller JP, Krebs ED, Hawkins RB, et al. Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing. JTCS. 2020;160:1222–31.

Google Scholar 

Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38:899–906.

PubMed  Google Scholar 

Koretsune Y, Yamashita T, Akao M, et al. Baseline demographics and clinical characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. Circ J. 2019;83:1538–45.

Article  PubMed  Google Scholar 

Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016. BMJ Open. 2019;9: e026645. https://doi.org/10.1136/bmjopen-2018-026645.

Article  PubMed  PubMed Central  Google Scholar 

Chang WT, Ho CH, Chang CL, Cheng BC, Wu NC, Chen ZC. Influence of warfarin on cardiac and cerebrovascular events following bioprosthetic aortic valve replacement: a nationwide cohort study. J Thorac Cardiovasc Surg. 2020;159:1730–9.

Article  PubMed  Google Scholar 

Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.

Article  CAS  PubMed  Google Scholar 

Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–9.

Article  CAS  PubMed  Google Scholar